Table 4. Evaluation of SF-36 domains physical functioning, physical role limitations, and emotional role limitations based on groups.

	PRP group			Placebo group			Total			p
	Mean±SD	Median	Min-Max	Mean±SD	Median	Min-Max	Mean±SD	Median	Min-Max
Physical functioning
Pre-treatment	33.61±23.19	30	0-95	36.25±16.25	37.5	10-60	34.67±20.42	32.5	0-95	0.551†
1-month post-treatment	32.69±18.89	30	0-65	43.50±27.39	40	10-100	37.39±23.05	40	0-100	0.512†
6-months post-treatment	42.31±21.08	40	0-75	51.5±34.65	40	5-100	46.30±27.48	40	0-100	0.618†
p value		0.352‡			0.237‡
Comparison
Pre-treatment vs. 1-month	4.62±21.55			5.00±17.32						0.926†
p value		1.000§			0.656§
Pre-treatment vs. 6-months	14.23±21.97			13.00±21.76						0.925†
p value		0.718§			0.438§
Physical role limitations
Pre-treatment	11.11±24.59	0	0-75	20.83±33.43	0	0-75	15.00±28.31	0	0-75	0.444†
1-month post-treatment	7.69±21.37	0	0-75	45.00±45.34	37.5	0-100	23.91±38.05	0	0-100	0.019*†
6-months post-treatment	26.92±34.55	0	0-100	50.00±48.59	50	0-100	36.96±41.88	25	0-100	0.234†
p value		0.055‡			0.076‡
Comparison
Pre-treatment vs. 1-month	0.00±10.21			20.00±48.30						0.068†
p value		0.922§			0.656§
Pre-treatment vs. 6-months	19.23±34.09			25.00±54.01						0.645†
p value		0.255§			0.438§
Emotional role limitations
Pre-treatment	25.92±42.09	0	0-100	36.11±43.71	16.7	0-100	30.00±42.3	0	0-100	0.440†
1-month post-treatment	25.64±43.36	0	0-100	33.33±41.58	16.7	0-100	28.98±41.81	0	0-100	0.500†
6-months post-treatment	48.72±46.38	33.3	0-100	60±46.62	83.4	0-100	53.62±45.77	66.7	0-100	0.573†
p value		0.072‡			0.276‡
Comparison
Pre-treatment vs. 1-month	-2.56±49.93			-10.00±41.73						0.751†
p value		1.000§			1.000§
Pre-treatment vs. 6-months	20.52±50.08			16.67±65.27						0.949†
p value		0.424§			0.943§
SF-36: Short Form Health Survey 36; PRP: Platelet-rich plasma; SD: Standard deviation; † Mann Whitney U test; ‡ Friedman test; § Wilcoxon corrected pairwise comparison; * p<0.05; ** p<0.01.